Cargando…
A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity
Mammalian INDY (mINDY, NaCT, gene symbol SLC13A5) is a potential target for the treatment of metabolically associated fatty liver disease (MAFLD). This study evaluated the effects of a selective, cross-species active, non-competitive, non-substrate-like inhibitor of NaCT. First, the small molecule i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413491/ https://www.ncbi.nlm.nih.gov/pubmed/36005604 http://dx.doi.org/10.3390/metabo12080732 |
_version_ | 1784775764441300992 |
---|---|
author | Zahn, Grit Willmes, Diana M. El-Agroudy, Nermeen N. Yarnold, Christopher Jarjes-Pike, Richard Schaertl, Sabine Schreiter, Kay Gehrmann, Wiebke Wong, Andrea Kuan Cie Zordan, Tommaso König, Jörg Jordan, Jens Birkenfeld, Andreas L. |
author_facet | Zahn, Grit Willmes, Diana M. El-Agroudy, Nermeen N. Yarnold, Christopher Jarjes-Pike, Richard Schaertl, Sabine Schreiter, Kay Gehrmann, Wiebke Wong, Andrea Kuan Cie Zordan, Tommaso König, Jörg Jordan, Jens Birkenfeld, Andreas L. |
author_sort | Zahn, Grit |
collection | PubMed |
description | Mammalian INDY (mINDY, NaCT, gene symbol SLC13A5) is a potential target for the treatment of metabolically associated fatty liver disease (MAFLD). This study evaluated the effects of a selective, cross-species active, non-competitive, non-substrate-like inhibitor of NaCT. First, the small molecule inhibitor ETG-5773 was evaluated for citrate and succinate uptake and fatty acid synthesis in cell lines expressing both human NaCT and mouse Nact. Once its suitability was established, the inhibitor was evaluated in a diet-induced obesity (DIO) mouse model. DIO mice treated with 15 mg/kg compound ETG-5773 twice daily for 28 days had reduced body weight, fasting blood glucose, and insulin, and improved glucose tolerance. Liver triglycerides were significantly reduced, and body composition was improved by reducing fat mass, supported by a significant reduction in the expression of genes for lipogenesis such as SREBF1 and SCD1. Most of these effects were also evident after a seven-day treatment with the same dose. Further mechanistic investigation in the seven-day study showed increased plasma β-hydroxybutyrate and activated hepatic adenosine monophosphate-activated protein kinase (AMPK), reflecting findings from Indy (−/−) knockout mice. These results suggest that the inhibitor ETG-5773 blocked citrate uptake mediated by mouse and human NaCT to reduce liver steatosis and body fat and improve glucose regulation, proving the concept of NaCT inhibition as a future liver treatment for MAFLD. |
format | Online Article Text |
id | pubmed-9413491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94134912022-08-27 A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity Zahn, Grit Willmes, Diana M. El-Agroudy, Nermeen N. Yarnold, Christopher Jarjes-Pike, Richard Schaertl, Sabine Schreiter, Kay Gehrmann, Wiebke Wong, Andrea Kuan Cie Zordan, Tommaso König, Jörg Jordan, Jens Birkenfeld, Andreas L. Metabolites Article Mammalian INDY (mINDY, NaCT, gene symbol SLC13A5) is a potential target for the treatment of metabolically associated fatty liver disease (MAFLD). This study evaluated the effects of a selective, cross-species active, non-competitive, non-substrate-like inhibitor of NaCT. First, the small molecule inhibitor ETG-5773 was evaluated for citrate and succinate uptake and fatty acid synthesis in cell lines expressing both human NaCT and mouse Nact. Once its suitability was established, the inhibitor was evaluated in a diet-induced obesity (DIO) mouse model. DIO mice treated with 15 mg/kg compound ETG-5773 twice daily for 28 days had reduced body weight, fasting blood glucose, and insulin, and improved glucose tolerance. Liver triglycerides were significantly reduced, and body composition was improved by reducing fat mass, supported by a significant reduction in the expression of genes for lipogenesis such as SREBF1 and SCD1. Most of these effects were also evident after a seven-day treatment with the same dose. Further mechanistic investigation in the seven-day study showed increased plasma β-hydroxybutyrate and activated hepatic adenosine monophosphate-activated protein kinase (AMPK), reflecting findings from Indy (−/−) knockout mice. These results suggest that the inhibitor ETG-5773 blocked citrate uptake mediated by mouse and human NaCT to reduce liver steatosis and body fat and improve glucose regulation, proving the concept of NaCT inhibition as a future liver treatment for MAFLD. MDPI 2022-08-08 /pmc/articles/PMC9413491/ /pubmed/36005604 http://dx.doi.org/10.3390/metabo12080732 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zahn, Grit Willmes, Diana M. El-Agroudy, Nermeen N. Yarnold, Christopher Jarjes-Pike, Richard Schaertl, Sabine Schreiter, Kay Gehrmann, Wiebke Wong, Andrea Kuan Cie Zordan, Tommaso König, Jörg Jordan, Jens Birkenfeld, Andreas L. A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title | A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title_full | A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title_fullStr | A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title_full_unstemmed | A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title_short | A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity |
title_sort | novel and cross-species active mammalian indy (nact) inhibitor ameliorates hepatic steatosis in mice with diet-induced obesity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413491/ https://www.ncbi.nlm.nih.gov/pubmed/36005604 http://dx.doi.org/10.3390/metabo12080732 |
work_keys_str_mv | AT zahngrit anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT willmesdianam anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT elagroudynermeenn anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT yarnoldchristopher anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT jarjespikerichard anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT schaertlsabine anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT schreiterkay anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT gehrmannwiebke anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT wongandreakuancie anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT zordantommaso anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT konigjorg anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT jordanjens anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT birkenfeldandreasl anovelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT zahngrit novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT willmesdianam novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT elagroudynermeenn novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT yarnoldchristopher novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT jarjespikerichard novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT schaertlsabine novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT schreiterkay novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT gehrmannwiebke novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT wongandreakuancie novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT zordantommaso novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT konigjorg novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT jordanjens novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity AT birkenfeldandreasl novelandcrossspeciesactivemammalianindynactinhibitorameliorateshepaticsteatosisinmicewithdietinducedobesity |